secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonoma Pharmaceuticals, Inc. (SNOA)
CIK:        0001367083
Form:       8-K
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0001683168-24-005980
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonoma Pharmaceuticals files prospectus supplement for existing at-the-market equity offering
--------------------------------------------------------------------------------

- Company entered into Equity Distribution Agreement with Maxim Group LLC on Dec 15, 2023, amended March 8, 2024.
- Prospectus supplement filed Aug 23, 2024 for sales of common stock under effective S-3 registration statement.
- Shares may be offered and sold through Maxim as sales agent or principal, at-the-market.
- Legal opinion of Polsinelli PC regarding share validity filed as Exhibit 5.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367083/000168316824005980/0001683168-24-005980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367083/000168316824005980/sonoma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer